46 related articles for article (PubMed ID: 17560737)
1. Fibrin glue mediated direct delivery of radiation sensitizers results in enhanced efficacy of radiation treatment.
Nguyen J; Chandekar A; Laurel S; Dosanjh J; Gupta K; Le J; Hirschberg H
Discov Oncol; 2024 Apr; 15(1):101. PubMed ID: 38573401
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
Huff SE; Winter JM; Dealwis CG
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
[TBL] [Abstract][Full Text] [Related]
3. The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.
Pepper NB; Stummer W; Eich HT
Strahlenther Onkol; 2022 Jun; 198(6):507-526. PubMed ID: 35503461
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and Radiosensitising Effects of a Novel Thioredoxin Reductase Inhibitor in Brain Cancers.
Yao A; Storr SJ; Inman M; Barwell L; Moody CJ; Martin SG
Mol Neurobiol; 2022 Jun; 59(6):3546-3563. PubMed ID: 35344158
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.
Thiabaud G; He G; Sen S; Shelton KA; Baze WB; Segura L; Alaniz J; Munoz Macias R; Lyness G; Watts AB; Kim HM; Lee H; Cho MY; Hong KS; Finch R; Siddik ZH; Arambula JF; Sessler JL
Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7021-7029. PubMed ID: 32179677
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mannargudi MB; Deb S
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
9. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS
J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM).
Krauze AV; Won M; Graves C; Corn BW; Muanza TM; Howard SP; Mahadevan A; Schultz CJ; Haas ML; Mehta MP; Camphausen KA
Biomark Res; 2013 Oct; 1(1):29. PubMed ID: 24252135
[TBL] [Abstract][Full Text] [Related]
11. Combined modality approaches in the management of adult glioblastoma.
Shirazi HA; Grimm S; Raizer J; Mehta MP
Front Oncol; 2011; 1():36. PubMed ID: 22655242
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.
McHaffie DR; Chabot P; Dagnault A; Suh JH; Fortin MA; Chang E; Timmerman R; Souhami L; Grecula J; Nabid A; Schultz C; Werner-Wasik M; Gaspar LE; Brachman D; Mody T; Mehta MP
J Neurooncol; 2011 Nov; 105(2):301-8. PubMed ID: 21523486
[TBL] [Abstract][Full Text] [Related]
13. JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.
Edes K; Cassidy P; Shami PJ; Moos PJ
PLoS One; 2010 Jan; 5(1):e8786. PubMed ID: 20098717
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pediatric brain tumors.
Karajannis M; Allen JC; Newcomb EW
J Cell Physiol; 2008 Dec; 217(3):584-9. PubMed ID: 18651562
[TBL] [Abstract][Full Text] [Related]
15. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
16. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
17. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
[TBL] [Abstract][Full Text] [Related]
18. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
[TBL] [Abstract][Full Text] [Related]
19. Motexafin gadolinium: a possible new radiosensitiser.
Rodrigus P
Expert Opin Investig Drugs; 2003 Jul; 12(7):1205-10. PubMed ID: 12831354
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
